Impact Biomedical Q2 FY26 net loss narrows 95% to $700,000
IBO•Q2 results
- Impact Biomedical posted a net loss of $700,000 for the quarter ended June 30, 2026, narrowing 95% year over year.
- Revenue fell 57% to $3,000, reflecting retail sales of its Celios air purification technology.
- Total costs and expenses dropped 39% to $705,000, led by a 78% decline in professional fees to $92,000.
Six-month performance and going concern warning
- For the six months ended June 30, net loss narrowed 81% to $2.98 million as revenue rose 43% to $10,000.
- Management flagged substantial doubt about continuing as a going concern, citing plans to monetize intellectual property and tightly control costs.
